Eli Lilly and Company is set to report first-quarter earnings, with a focus on the impact of weight-loss drugs Zepbound and Mounjaro.
🟢 Short-term forecast: +-0.0%
🔴 Long-term forecast: +1.1%
Stock AI’s (LLY) Forecast get (+5.4% Profit)
StockAI’s analysis delivers real-world results. On 04 March 2024, $LLY ($795.4), StockAI predicted a long-term 🔴 sell signal. It was accurate: 1 month later price dropped to $752.1 (🔴-5.4%). Selling LLY on this signal yielded a +5.4% profit 💰💰.
LLY-Eli Lilly and Company News
🟢 Eli Lilly to report first-quarter earnings on April 30, with expectations of $8.9 billion in sales and $2.46 in adjusted earnings per share. 🟢 The pharmaceutical giant is set to post its quarterly earnings before the market opens. 🟢 Goldman Sachs raises price target for LLY from $650.00 to $723.00, with a neutral rating on the stock. 🟢 Cantor Fitzgerald reaffirms “overweight” rating on LLY with a $815.00 price target. 🟢 Citigroup increases price target for LLY from $675.00 to $895.00, maintaining a “buy” rating. 🟢 Zacks Research boosts Q1 2026 earnings estimates for Eli Lilly and Company.
The recent news surrounding Eli Lilly and Company stock has been mostly positive, with analysts raising price targets and earnings estimates. The upcoming first-quarter earnings report is expected to show strong sales and adjusted earnings per share, which has boosted investor confidence. With several investment firms maintaining “buy” ratings and increasing price targets, the overall sentiment towards LLY stock is optimistic. These developments may lead to a positive impact on the stock price in the short-term and long-term, potentially driving a 1.1% increase as forecasted. Investors should keep an eye on the earnings report and any updates from analysts to gauge the future performance of Eli Lilly and Company stock.
LLY-Eli Lilly and Company Analyst Ratings
In recent analyst ratings for Eli Lilly and Company (NYSE:LLY) stock, we see the following changes:
📉 Citigroup raised their price target on Eli Lilly and Company from $675.00 to $895.00 and maintained a “buy” rating on the stock.
📈 Cantor Fitzgerald reaffirmed their “overweight” rating on Eli Lilly and Company and set a price target of $815.00.
📉 Zacks Research decreased their Q1 2026 earnings estimates for Eli Lilly and Company.
Sources:
– ETF Daily News – Citigroup raises price target on Eli Lilly and Company
– ETF Daily News – Cantor Fitzgerald maintains “overweight” rating on Eli Lilly and Company
– ETF Daily News – Zacks Research lowers earnings estimates for Eli Lilly and Company
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
